We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The U.S. Food and Drug Administration (FDA) approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.
Lilly has reported mixed trial data for its experimental therapy galcanezumab, showing efficacy in patients with episodic cluster headaches but failing in those with chronic cluster headache.